Toxicity Issues Halt PBT1 Program In Alzheimer's; Prana's Stock Falls April 12, 2005 By Jennifer Boggs
Northfield's PolyHeme Passes Third Phase III Interim Analysis April 12, 2005 Northfield Laboratories Inc.'s stock jumped 31.6 percent Monday after an independent data monitoring committee gave the go-ahead for the ongoing Phase III trial of PolyHeme. (BioWorld Today)Read More
RSS